medigraphic.com
ISSN 1561-3062 (Electronic)

2017, Number 1

Next >>

Revista Cubana de Obstetricia y Ginecología 2017; 43 (1)

Risk factor behavior in patients with abnormal cytologies in Miranda state, Venezuela

Montesino AJC, Arronte SME, Matos RA, Arias PDE, Fernández LA

Language: Spanish
References: 24
Page: 1-11
PDF size: 111.19 Kb.


ABSTRACT

Introduction: The study of risk factors associated with cervical cancer is important taking into account the prevalence of this pathology worldwide.
Objective: Identify the associated biological and behavioral risk factors to abnormal cytological results.
Methods: A descriptive observational study was conducted in a universe of 872 women who presented abnormal cytological results at the Clinical Laboratory of Misión Barrio Adentro, Miranda State in 2015. The primary data were obtained from the cytology card reader, also from the results of the application of a form made to that effect in accordance with the proposed objectives. Tis form was applied in neck pathology consultations. Descriptive statistics, frequency distribution and percent were used as statistical method, the processed results were presented in texts and tables.
Results: 45 % of those studied belonged to the age group from 35 to 44 years old, with a family history of cancer in 61.6 % and multiparous women accounting for 74.9 %. The history of genital infection was present in 70.9 %. that is, 58.5 % had HPV infection, while promiscuity covered 62.5 %. The predominated cytologic result was cervical intraepithelial neoplasia grade II, present in 46 % of the women studied.
Conclusions: There was predominance of abnormal cytological results in women, with a family history of cancer and multiparas corresponding to the age group of 35-44 years.


REFERENCES

  1. Chirenje M. El impacto global del cáncer de cuello uterino. 2015. [citado 20 de mayo de 2016]. En: http://www.rho.org/aps/media/01_Mike_Global_Impact.pdf

  2. Globocan 2008. Breast Cancer Incidence, Mortality and Prevalence Worldwide in 2008. Summary. [citado 20 de mayo de 2014]. Disponible en: http://globocan.iarc.fr/factsheet.asp

  3. Origoni M, Carminati G, Rolla S, Clementi M, Sideri M, Sandri MT. Candiani. Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology. Eur J Clin Microbiol & Infect Dis. 2012.

  4. Castellsagué X, Bruni L, Alemany L, Diaz M, de Sanjosé S, Bosch FX. The epidemiology of cervical cancer. HPV and Cervical Cancer. 2012:63-83.

  5. Kärrberg C. Cervical dysplasia and cervical cancer in pregnancy: diagnosis and outcome. [disertation]. Department of Obstetrics and Gynecol. Institute of Clinical Sciences. The Sahlgrenska Academy, University of Gothenbrug, Göteborg, Sweden. 2012.

  6. Amirian ES, Adler-Storthz K, Scheurer ME. Associations between human herpesvirus-6, human papillomavirus and cervical cancer. Cancer Lett. 2013;336(1):18-23.

  7. Munk AC, Gudlaugsson E, Malpica A, Fiane B, Løvslett KI. Consistent Condom Use Increases the Regression Rate of Cervical Intraepithelial Neoplasia 2-3. PLoS ONE. 2012;7(9).

  8. Popadiuk C, Stankiewicz A, Dickinson J, Pogany L, Miller AB, Onysko J. Invasive cervical cancer incidence and mortality among canadian women aged 15 to 29 and the impact of screening. J Obstet Gynaecol Can. 2012;34(12);1167-76.

  9. Van Bogaert LJ. P16INK4a immunocytochemistry/immunohistochemistry: need for scoring uniformization to be clinically useful in gynecological pathology. Annals of Diagnostic Pathol. 2012;24.

  10. Ibfelt E, Kjaer SK, Johansen C, Høgdall C, Steding-Jessen M, Frederiksen K, et al. Socioeconomic Position and Stage of Cervical Cancer in Danish Women Diagnosed 2005 to 2009. Cancer Epidemiol Biomarkers Prev. 2012;21:835.

  11. Charlton B, Carwile JL, Michels KB, Feldman S. A cervical abnormality risk prediction model: can we use clinical information to predict which patients with ASCUS/LSIL Pap test will develop CIN 2/3 or AIS?. J Low Genital Tract Disease. 2013.

  12. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of HPV. Vaccine. 2012;30(5).

  13. Firnhaber C, Mayisela N, Mao L, Williams S, Swarts A. Validation of Cervical Cancer Screening Methods in HIV Positive Women from Johannesburg South Africa. PLoS ONE. 2013;8(1).

  14. MINSAP. Cuba. Programa de detección oportuna de lesiones malignas y premalignas del cuello uterino. 2001.

  15. Zeng SY, Liang MR, Li LY, Wu YY. Comparison of the efficacy and complications of different surgical methods for cervical intraepithelial neoplasia. Eur J Gynaecol Oncol. 2012;33(3):257-60.

  16. Braillard M, Braverman A, Nahuel M, Chapier V. Cáncer de cervix: incidencia según edad y estadio tumoral Revista de Posgrado de la Via Cátedra de Medicina. 2005;141:7-10.

  17. Soler R, Papua A. Neoplasias intrapiteliales múltiples asociadas al VPH. Rev. HPV Today. 2007;13:14-5.

  18. Fox PA, Tung MY. Human papillomavirus, burden of illness and treatment cost considerations. Am J Clin Dermatol. 2005;6:365-81.

  19. Lomalisa P, Smith T, Guidozzi F. Human immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecological Oncology. 2006;77(3):460-3.

  20. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. 2012

  21. Massad LS, Einstein MH, Huh WK. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease. 2013;17(5).

  22. Bethesda, MD. Cervical cancer. National Cancer Institute. 2014

  23. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute. 2012.

  24. Hacker DG, Edwards BK, Tucker MA, Fraumeni JF. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. 2006.




2020     |     www.medigraphic.com